| Literature DB >> 36118631 |
Paraskevas Gkolfakis1, Pauline Van Ouytsel1, Youssef Mourabit1, Michael Fernandez1, Rawad Yared1, Jacques Deviere1, Vincent Huberty1.
Abstract
Background and study aims This was a single-blind, single-center, prospective randomized controlled trial aimed at comparing the efficacy of three different suture patterns for endoscopic sleeve gastroplasty using Endomina (E-ESG). Patients and methods The suture patterns aimed to modify gastric accommodation by increasing the fundus distention ability (Group A), to reduce gastric volume (Group B) or to interrupt gastric emptying (Group C). Patients were randomized 1:1:1 and underwent clinical follow-up, gastric emptying scintigraphy, and satiety tests at baseline and 6 and 12 months post-procedure. The primary outcome was total body weight loss (TBWL) and excess weight loss (EWL) at 12 months post-procedure. Secondary outcomes included the impact of the suture patterns on gastric emptying and satiety. Results Overall, 48 patients (40 [83.3 %] female, aged 41.9 ± 9.5 years, body mass indexI 33.8 ± 2.7 kg/m 2 ) were randomized (16 in each group). In the entire cohort, mean (95 % confidence interval [CI]) TBWL and EWL at the end of the follow-up were 10.11 % (7.1-13.12) and 42.56 (28.23-56.9), respectively. There was no difference among the three study groups in terms of TBWL (95 %CI) (9.13 % [2.16-16.11] vs. 11.29 % [5.79-16.80] vs. 9.96 % [4.58-15.35]; P = 0.589) and EWL (95 %CI) (34.54 % [6.09-62.99] vs. 44.75 % [23.63-65.88] vs. 46.94 % [16.72-77.15]; P = 0.888) at 12 months post-procedure. The three groups did not differ in terms of mean gastric emptying time or in terms of satiety tests at the end of the follow-up. No serious adverse events occurred. Conclusions Three different suture patterns during E-ESG demonstrated comparable efficacy in terms of weight loss, with an overall EWL of > 25 % and TBWL of > 10 % at 12 months. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).Entities:
Year: 2022 PMID: 36118631 PMCID: PMC9473843 DOI: 10.1055/a-1880-7580
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Fig. 1Graphic illustration and final endoscopic image of the three suture patterns and their respective endoscopic results post-procedure. a Pattern “band” aiming to increase distensibility of the fundus. b Gastric “volume reduction.” c Pattern “dams” aiming to slow down gastric emptying.
Fig. 2Study flowchart.
Baseline demographic, anthropometric, and laboratory parameters of enrolled patients.
|
|
|
| |
| Sex, n (%) | |||
Female | 14 (87.5) | 13 (81.3) | 13 (81.3) |
Male | 2 (12.5) | 3 (18.7) | 3 (18.7) |
| Smoking status, n (%) | |||
Never | 8 (50) | 13 (81.3) | 12 (75) |
Past | 2 (12.5) | 1 (6.2) | 2 (12.5) |
Active | 6 (37.5) | 2 (12.5) | 2 (12.5) |
| Alcohol, n (%) | |||
Never | 8 (50) | 12 (75) | 10 (62.5) |
Past | 0 (0) | 1 (6.2) | 0 (0) |
Active | 8 (50) | 3 (18.8) | 6 (37.5) |
| Age (years), mean (SD) | 42.81 (7.95) | 36.75 (6.78) | 44.25 (11.2) |
| Weight (kg), mean (SD) | 93.81 (10.24) | 91.79 (7.84) | 90.23 (11.67) |
| Height (cm), mean (SD) | 165 (7) | 165 (7) | 164 (8) |
| BMI (kg/m 2 ), mean (SD) | 34.65 (2.55) | 33.8 (2.69) | 33.34 (2.51) |
| Fat Mass | 40.9 (4.76) | 39.23 (6.3) | 41.04 (19.84) |
| Glucose (mg/dL), mean (SD) | 97.6 (14.9) | 92.46 (12) | 94.31 (9.68) |
| Total cholesterol (mg/dL), mean (SD) | 185.69 (50.03) | 172.64 (44.34) | 212.25 (48.95) |
| HDL cholesterol (mg/dL), mean (SD) | 51.54 (12.19) | 57.07 (16.28) | 57.44 (12.75) |
| Triglycerides (mg/dL), mean (SD) | 146.93 (105.92) | 96.64 (41.36) | 127.06 (71.66) |
| AST | 19.4 (11.59) | 20.13 (5.63) | 19.13 (6.28) |
| ALT | 22.07 (13.37) | 19.93 (7.18) | 22.63 (12.8) |
| gGT | 24.07 (16.42) | 20.53 (13.48) | 24.06 (16.12) |
| ALP | 76.67 (28.24) | 79.25 (10.72) | 46 (21.31) |
BMI, body mass index; AST, aspartate transaminase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; gGT, gamma glutamyl transferase; HDL, high density lipoprotein.
Fig. 3 Percentage of total body weight loss (TBWL%) and excess weight loss (EWL%) according to suture pattern during follow-up.
Total body weight loss and excess weight loss over time.
|
|
|
|
| |||||
|
|
|
|
|
|
| |||
| Month 1 | (n = 15) 5.24 (4.04–6.44) | (n = 15) 5.89 (4.50–7.28) | (n = 14) 5.74 (4.20–7.29) |
0.589
| (n = 15)1 9.46 (14.58–24.34) | (n = 15) 23.89 (16.92–30.86) | (n = 14) 24.55 (15.81–33.29) |
0.888
|
| Month 3 | (n = 13) 10.35 (8.21–12.48) | (n = 13) 9.70 (7.33–12.07) | (n = 15) 8.92 (5.67–12.16) | (n = 13) 37.54 (29.77–45.32) | (n = 13) 39.93 (30.97–48.89) | (n = 15) 41.91 (24.12–59.69) | ||
| Month 6 | (n = 11) 11.93 (7.67–16.19) | (n = 13) 10.75 (6.96–14.55) | (n = 14) 10.57 (6.27–14.86) | (n = 11) 45.15 (27.68–62.62) | (n = 13) 41.96 (27.37–56.56) | (n = 14) 49.60 (26.12–73.08) | ||
| Month 9 | (n = 11) 12.55 (7.62–17.48) | (n = 13) 9.81 (5.28–14.35) | (n = 15) 10.28 (6.08–14.49) | (n = 11) 47.55 (26.11–68.98) | (n = 11) | (n = 15) 47.60 (23.90–71.31) | ||
| Month 12 | (n = 11) 9.13 (2.15–16.11) | (n = 13) 11.29 (5.79–16.80) | (n = 15) 9.96 (4.58–15.35) | (n = 11) 34.54 (6.09–62.99) | (n = 13) | (n = 15) 46.94 (16.72–77.15) | ||
TBWL, total body weight loss; EWL, excess weight loss; n: available data in that time; data are analyzed as ITT using mixed models.
Comparison among the three groups at month 12.
Results of gastric emptying scintigraphy over time.
| Half time emptying (min), mean (95 % CI) | |||||||
| Group A | Group B | Group C | |||||
| Baseline | (n = 16) 57.50 (43.64–71.36) |
0.999
| (n = 16) 59.64 (46.91–72.37) |
0.945
| (n = 16) 68.07 (59.86–76.27) |
0.999
|
0.577
|
| Month 6 | (n = 8) 57.50 (40.48–74.52) | (n = 9) 65.56 (45.29–85.82) | (n = 8) 61.25 (45.51–76.99) | ||||
| Month 12 | (n = 6) 54.00 (32.86–75.14) | (n = 8) 68.38 (48.25–88.50) | (n = 11) 69.45 (55.05–83.86) | ||||
n, available data in that time; data are analyzed as ITT using mixed models.
CI, confidence interval; ITT, intention to treat.
Per group comparison between baseline and month 12.
Time-group interaction for the three groups at month 12.
Results of drinking satiety test over time.
|
Volume to reach endpoint
| |||||||
| Group A | Group B | Group C | |||||
| Baseline | (n = 16) 375.63 (299.69–451.56) |
0.330
| (n = 16) 444.38 (303.41–585.34) |
0.077
| (n = 16) 513.13 (368.10–658.15) |
0.214
|
0.875
|
| Month 6 | (n = 8) 221.25 (138.68–303.82) | (n = 9) 253.33 (135.69–370.98) | (n = 10) 297.00 (160.72–433.28) | ||||
| Month 12 | (n = 7) 268.57 (130.11–407.03) | (n = 7) 231.43 (162.13–300.73) | (n = 10) 401.00 (34.78–767.22) | ||||
n, available data in that time; data are analyzed as ITT using mixed model.
CI, confidence interval; ITT, intention to treat.
Hunger, fullness, nausea, bloating, and pain according to protocol.
Per group comparison between baseline and month 12.
Time-group interaction for the three groups at month 12.
Adverse events assessed at 24 hours post-procedure using a 0–10 visual analogue scale.
|
|
|
|
| |
| Nausea, mean (SD) | 1.27 (1.87) | 2.25 (2.84) | 1.88 (2.31) | 0.690 |
| Vomiting, mean (SD) | 1.27 (3.03) | 1.94 (3.36) | 0.94 (2.57) | 0.483 |
| Cramps, mean (SD) | 4.40 (2.59) | 4.25 (2.67) | 3.63 (2.53) | 0.617 |
SD, standard deviation.